SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Seac - Seachange New IPO
SEAC 3.350-4.3%Oct 22 10:15 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: caly who wrote (392)3/9/2000 2:10:00 PM
From: alex s.  Read Replies (1) of 431
 
positive mention on cnbc gave a little more detail
as to seac VOD niche..article below is the gist of the general commentary from the fund manager interviewed etc...:

Tech, Biotech Sectors Likely To Continue Runs
-Fund Mgr

Dow Jones Newswires

NEW YORK -- Technology and biotechnology sectors are likely to continue their positive runs for a long time, said Ken Mertz, portfolio manager of HomeState PA Growth Fund.

In a CNBC interview Thursday, Mertz said, "We think capital spending is being devoted to technology and as long as business needs to get more productive," the technology
sector will deliver.

Additionally, biotechs have severely underperformed for the past six to seven years, and the recent upswing is in the "first leg," he said.

Mertz likes Clarus Corp. (CLRS), the fund's largest holding. Clarus is an e-procurement services company that serves the middle-market area.

He also suggested Safeguard Scientifics Inc. (SFE), an Internet incubator of business-to-business plays. Even at current levels, Mertz sees the issue as a buy. He
expects that up to 10 companies currently being incubated by Safeguard will go public this year, giving Safeguard's investors a right to buy these shares.

Mertz likes Emisphere Technologies Inc. (EMIS), which is developing oral-delivery technology for previously injectable-only agents. It is in phase III trials of its oral-heparin drug.

He also likes Seachange International Inc. (SEAC).

-Beth M. Mantz; Dow Jones Newswires; 201-938-5393
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext